Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico

Core Insights - Oragenics, Inc. will present at the Sequire Investor Summit 2026, scheduled for January 20th-22nd, 2026, in San Juan, Puerto Rico [1] - The company aims to address the unmet medical need in concussion and mild traumatic brain injury with its lead candidate, ONP-002, which is advancing to Phase 2a clinical studies [2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing Phase 2a trials in Australia and planned Phase IIb trials in the U.S. [3] - The intranasal delivery platform has potential applications for various neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders [3] Industry Context - Puerto Rico is an attractive location for investors due to its favorable tax benefits, making it home to many family offices and wealthy investors [2]